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ABSTRACT: The iron storage protein bacterioferritin (BfrB) is central to
bacterial iron homeostasis. The mobilization of iron from BfrB, which requires
binding by a cognate ferredoxin (Bfd), is essential to the regulation of
cytosolic iron levels in P. aeruginosa. This paper describes the structure-guided
development of small molecule inhibitors of the BfrB−Bfd protein−protein
interaction. The process was initiated by screening a fragment library and
followed by obtaining the structure of a fragment hit bound to BfrB. The
structural insights were used to develop a series of 4-(benzylamino)- and 4((3-phenylpropyl)amino)-isoindoline-1,3-dione analogs that selectively bind
BfrB at the Bfd binding site. Challenging P. aeruginosa cells with the 4-substituted isoindoline analogs revealed a dose-dependent
growth phenotype. Further investigation determined that the analogs elicit a pyoverdin hyperproduction phenotype that is
consistent with blockade of the BfrB−Bfd interaction and ensuing irreversible accumulation of iron in BfrB, with concomitant
depletion of iron in the cytosol. The irreversible accumulation of iron in BfrB prompted by the 4-substituted isoindoline analogs
was conﬁrmed by visualization of BfrB-iron in P. aeruginosa cell lysates separated on native PAGE gels and stained for iron with
Ferene S. Challenging P. aeruginosa cultures with a combination of commercial ﬂuoroquinolone and our isoindoline analogs
results in signiﬁcantly lower cell survival relative to treatment with either antibiotic or analog alone. Collectively, these ﬁndings
furnish proof of concept for the usefulness of small molecule probes designed to dysregulate bacterial iron homeostasis by
targeting a protein−protein interaction pivotal for iron storage in the bacterial cell.

■

INTRODUCTION

and third-generation cephalosporin resistant Enterobacteriaceae.4 P. aeruginosa is one of the leading Gram-negative
pathogens associated with hospital infections due to their
propensity to colonize urinary catheters and endotracheal
tubes5,6 and accelerate lung function decay that lowers the
survival of cystic ﬁbrosis patients.7,8 Responding to this call
requires vibrant research and continued investment in the early
stages of drug development, in order to ensure a pipeline of
novel ideas and approaches.5 In this context, strategies that
interfere with bacterial iron acquisition and homeostasis are

Antibiotic resistant infections are a worldwide threat to public
health. The challenge posed by the emergence of antibiotic
resistant strains is compounded by slow to nearly stalled
development of new antibiotics and validation of new
targets.1−3 Hence, antibiotic resistant infections have the
potential to undermine many achievements in modern
medicine, such as organ transplantation, major surgery, and
cancer chemotherapy. The World Health Organization
(WHO) published a priority list for research and development
of new antibiotics to combat multidrug resistant bacteria, and
assigned critical priority to the Gram-negative carbapenemresistant Acinetobacter baumanii and Pseudomonas aeruginosa,
© 2019 American Chemical Society
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Figure 1. Structure and function of BfrB, Bfd, and the BfrB−Bfd complex. (A) BfrB is a nearly spherical molecule assembled from 24 identical
subunits and 12 hemes. The 24-mer assembly harbors a hollow cavity approximately 80 Å in diameter where iron is stored in the form of a Fe3+
mineral. (B) Each heme molecule (red) is buried at the interface of a subunit dimer (green and gray), with the heme propionates protruding into
the interior cavity. Each molecule of Bfd (cyan) binds BfrB at the subunit dimer interface to facilitate electron ﬂow from the [2Fe−2S] cluster
(orange and yellow spheres) in Bfd to the Fe3+ mineral in the interior cavity of BfrB through a heme, thus promoting the mobilization of Fe2+. (C)
Zoomed-in view of the BfrB−Bfd protein−protein interface, depicting the proximity of the [2Fe−2S] cluster in Bfd (orange and yellow) to the
BfrB surface, as well as the burial of key Bfd residues (Y2 and L5) on pockets formed at the BfrB surface by residues L68 and E81.

regarded as having potential as new therapeutic interventions.9−13 Iron is essential for bacteria because of its
involvement in multiple metabolic processes, including
respiration and fundamental enzymatic reactions.14 Pathogenic
bacteria must obtain iron from the host, but host nutritional
immunity maintains extremely low concentrations of free iron,
thus denying the essential nutrient to invading pathogens.15−18
In addition, the very low solubility of the ferric ion (Fe3+)
severely limits its bioavailability, and the reactivity of the
soluble ferrous iron (Fe2+) toward hydrogen peroxide and
oxygen induces oxidative stress. Consequently, the processes of
bacterial iron homeostasis (acquisition, storage and utilization)
are highly regulated to ensure suﬃciency for metabolic needs
while preventing iron-induced toxicity.19,20 Herein, we describe
a new approach to dysregulate iron homeostasis in P.
aeruginosa that utilizes small molecule probes designed to
block the interaction between the iron storage protein
bacterioferritin B (BfrB) and its cognate partner, the
bacterioferritin-associated ferredoxin (Bfd).
Bacteria store iron reserves in bacterial ferritin (Ftn) and in
bacterioferritin (Bfr).21−23 The roughly spherical and hollow
structures of Bfr and bacterial Ftn, which are formed from 24
identical subunits, have an outer diameter of ∼120 Å, an inner
diameter of ∼80 Å, and an interior cavity that can store up to
∼3000 iron ions in the form of a Fe3+ mineral (Figure 1A).
Bfrs, which exist only in bacteria, bind 12 heme groups buried
under the external protein surface, with the heme propionates
protruding into the interior cavity.21,22 Despite sharing a nearly
identical subunit fold and quaternary structures, the eukaryotic
Ftns and the Bfrs share less than 20% sequence similarity,
which results in divergent subunit packing, 24-mer dynamics
and function.23−26 Although in P. aeruginosa the f tnA and bfrB
genes encode a bacterial ferritin (FtnA) and a bacterioferritin
(BfrB), respectively,27,28 BfrB functions as the main iron
storage protein.19 Importantly, the mobilization of iron stored
in BfrB requires speciﬁc interactions with Bfd.19,23,29 A crystal
structure of the BfrB−Bfd complex revealed that up to 12 Bfd
molecules can bind at identical sites on the BfrB surface, at the
interface of subunit dimers, above a heme molecule (Figure
1B).30 Characterization of the complex in solution showed that
the 12 Bfd binding sites are equivalent and independent, and
that Bfd binds to BfrB with a Kd of approximately 3 μM.31

These investigations also revealed that M1, Y2, and L5 in Bfd
form a continuous set of interactions with L68 and E81 in
BfrB, which contribute signiﬁcantly to the stabilization of the
BfrB−Bfd complex (Figure 1C). In agreement, the Kd values
for the association between Bfd and the L68A or E81A
mutants of BfrB are approximately 100-fold larger, and the
association between Bfd and the BfrB L68A/E81A double
mutant is undetectable.31
The repercussions of blocking the BfrB−Bfd interaction on
P. aeruginosa iron metabolism have been investigated by
deleting the bfd gene. These investigations, which showed an
irreversible accumulation of Fe3+ in BfrB with concomitant
iron deprivation in the cytosol, established the BfrB−Bfd
interaction as a novel target to rationally induce iron
homeostasis dysregulation in bacteria.19 Consequently, it is
important to discover small molecule inhibitors of the BfrB−
Bfd interaction, which can be used as chemical probes to study
bacterial iron homeostasis and uncover additional vulnerabilities in the bacterial cell exposed by iron metabolism
dysregulation. Chemical probes are a powerful complement to
the utilization of genetic techniques because they oﬀer dosedependent, selective, and temporal control over target proteins,
which can be utilized in combination with other synergistic or
antagonistic probes.32,33 Herein we present the results from a
structure-guided program aimed at the development of small
molecules designed to inhibit the BfrB−Bfd interaction in P.
aeruginosa. These novel probes are capable of penetrating the
bacterial cells, where they inhibit the mobilization of iron from
BfrB and elicit perturbations in iron homeostasis that decrease
bacterial ﬁtness, and also potentiate the bactericidal activity of
ﬂuoroquinolone antibiotics.

■

EXPERIMENTAL SECTION

Chemicals, Strains, and Growth Media. Chemicals were
purchased from Fisher Scientiﬁc unless otherwise stated. Pseudomonas
aeruginosa (PAO1) was purchased from the University of Washington
Genome Center. The PAO1-derived strain with an unmarked, inframe deletion of the bfrB gene had been prepared previously.19 P.
aeruginosa clinical isolates (MR3B and MR60) were obtained from
Seattle Children’s Research Foundation. [The clinical isolates of P.
aeruginosa (strains isolated from the lungs of people with cystic
ﬁbrosis) were obtained from Seattle Children’s Research Institute via
the Antimicrobial Tools and Resources (Microbial Resources)
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Growth Curves and IC50 Determination. Precultures (5 mL LB
media) were grown for 12 h at 37 °C and 220 rpm in 50 mL conical
tubes (VWR International, PA) covered with an air permeable
membrane. The cells were then centrifuged at 4000 rpm for 10 min,
and the resultant cell pellets were washed twice in M63 media and
then diluted in M63 media to OD600 = 0.01. Stock solutions (100
mM) of analog in DMSO were prepared weekly and stored at 4 °C.
Prior to initiating experiments in 96 well plates, the analog stock
solution was serially diluted to make 10 mM or 1 mM working
solutions in DMSO. A small volume of the appropriate working
solution was transferred to a glass vial, diluted with DMSO to 30 μL,
and then diluted to a ﬁnal volume of 1.5 mL with preculture cell
suspension with an OD600 = 0.01. The resultant cell suspension (200
μL) was transferred to a clear-bottom polystyrene 96 well plate
(VWR) and incubated at 35 °C and 205 cpm for 13 h in an Epoch 2
microplate spectrophotometer (Biotek Instruments, Inc., Vermont).
The growth curve in the presence of Ciproﬂoxacin was obtained in
the same plate. To this end, 11.2 μL of a Ciproﬂoxacin working
solution (100 μg/mL) were mixed with 30 μL of DMSO prior to
diluting to a ﬁnal volume of 1.5 mL with cell suspension having an
OD600 = 0.01 and transferring to the plate. The resultant
concentration of ciproﬂoxacin in the wells was 0.75 μg/mL, which
is equivalent to 3 times the reported MIC.45 Each condition was
replicated in 5 wells of the plate, so the growth curves shown in
Figures 5 and S5 are constructed from the average and standard
deviation of 5 replicates. The growth % was estimated using the
OD600 values obtained 13 h postinoculation and eq 1, where ODT is
the optical density of the culture treated with analog, ODU is the
optical density of the untreated control, and ODCip is the optical
density of the culture treated with ciproﬂoxacin. To calculate the IC50
values, the growth % was plotted as a function of log[analog (μM)]
and ﬁtted to eq 2, where the terms are deﬁned as above and b is the
slope factor.46

services oﬀered by the Cystic Fibrosis Foundation (https://www.cﬀ.
org/Research/Researcher-Resources/Tools-andResources/Antimicrobial-Tools-and-Resources/).] All strains were
kept on Pseudomonas Isolation Agar (PIA) (BD Biosciences, CA).
M63 media was prepared as previously reported,34 with a small
modiﬁcation. It contained per liter the following: 2 g of (NH4)2SO4,
13.6 g of KH2PO4 (Sigma-Aldrich), 2 g of glucose, 4 g of citric acid,
0.25 g of tryptophan (Acros organics), 5 g of nontechnical grade
casamino acids (BD scientiﬁc), and 0.24 g of MgSO4 (Alfa Aesar),
and the pH was adjusted to 7.0 with KOH. The M63 media also
contained 0.1% (w/v) of hypermellose (HPMC, Sigma-Aldrich) to
prevent aggregation of the analogs in aqueous solution.35 Colorimetric analysis showed that the M63 media contains 2 μM Fe. When
necessary, the M63 media was supplemented with additional iron by
addition of a small volume of 1 mM (NH4)2Fe(SO4)2 (pH ≈ 2.0) to
give the desired ﬁnal iron concentration.
Fragment Library Screening Using Saturation Transfer
Diﬀerence (STD) NMR Spectroscopy. Experimental details are
presented in the Supporting Information.
Synthesis and Preparation of Analogs. Experimental details of
the synthetic procedures developed to prepare compounds to be
tested as inhibitors of the BfrB−Bfd interaction, as well as the
corresponding 1H and 13C NMR spectra, are presented in the
Supporting Information.
Crystallization, Ligand Soaking, and Data Collection.
Crystallization screening was conducted in Compact 300 (Rigaku
Reagents) sitting drop vapor diﬀusion plates at 18 °C using equal
volumes (0.5 μL) of BfrB and crystallization solution equilibrated
against 75 μL of the latter. Three diﬀerent BfrB constructs were
investigated to grow crystals of BfrB suitable for soaking experiments
with the diﬀerent fragments and analogs. BfrB crystals were observed
in 1−2 days as follows: C89S/K96C BfrB: Red prismatic crystals were
obtained from Wizard 1−2 (Rigaku Reagents) condition E2 (35% (v/
v) 2-methyl-2,4-pentanediol, 100 mM MES 6.5, 200 mM Li2SO4).
Apo-BfrB (BfrB devoid of heme): Colorless prismatic, or light yellow,
crystals were obtained from the Wizard 3−4 screen (Rigaku
Reagents) condition B1 (8% (w/v) PEG 8000, 100 mM Na acetate
pH 4.6). BfrB: Red plates grew from the Cryo 1−2 HT screen
(Rigaku Reagents) condition H6 (30% (v/v) PEG 200, 100 mM Na
acetate pH 4.5, 100 mM NaCl). To prepare for soaking experiments, a
stock solution (100 mM in DMSO) of each fragment or analog
(compound) was mixed with crystallization solution to obtain a 20
mM compound solution to be used in soaking experiments. Crystals
were transferred to these soaking solutions and incubated for 3.0 to
3.5 h before harvesting directly from the drop and storing in liquid
nitrogen. Analog 13 was soaked in a 25 mM compound solution for 2
h, and analog 16 was soaked in a 10 mM compound solution for 3 h.
The compound soaking solutions, which also served as the
cryoprotectant, contained 80% crystallization solution and 20%
DMSO. Structures of compounds bound to BfrB were obtained
from the following compound/BfrB crystal combinations: Fragment
1/C89S/K96C BfrB, analog 12/apo-BfrB, and analogs 11, 13, 14, 15,
16/BfrB. X-ray diﬀraction data were collected at the Advanced
Photon Source beamline 17-ID using a Dectris Pilatus 6 M pixel array
detector.
Structure Solution and Reﬁnement. Intensities were integrated
using XDS,36 via Autoproc,37 and the Laue class analysis and data
scaling were performed with Aimless.38 Structure solution was
conducted by molecular replacement with Phaser,39 and structure
reﬁnement and manual model building were performed with Phenix40
and Coot,41 respectively. Electron density omit maps for the ligands
were calculated using the Polder omit routine42 with the Phenix
software suite. Structure validation was carried out with Molprobity,43
and ﬁgures were prepared with CCP4mg.44 The search models used
for molecular replacement were as follows: C89S/K96C BfrB (PDB:
4TOF)26 and BfrB (PDB: 5D8O).31 Apo-BfrB: Structure solution was
carried out using a single subunit of a previously determined structure
of BfrB as the search model (PDB: 3IS7).28 The top solution was
obtained in the space group C2221 with 12 molecules in the
asymmetric unit.

growth % =

(ODT − ODCip)
(ODU − ODCip)

growth % = ODCip +

× 100
(1)

ODU − ODCip
1+

(

log[analog(μM)]
IC50

−b

)

(2)

Analysis of Secreted Pyoverdin. These experiments were
carried out in 96 well plates, as described above. P. aeruginosa cells
treated with analog 11 or 16 (125 μM ﬁnal concentration) were
cultured for 13 h before the contents of each well were serially diluted
in phosphate buﬀered saline (PBS, pH 7.4) and then plated on PIA
plates to enumerate viable cells. The 500-fold diluted solution was
centrifuged, and the cell-free supernatant was analyzed for pyoverdin
by ﬂuorescence spectrophotometry in a Synergy H1 microplate reader
(Bioteck) with excitation at 400 nm and emission at λmax = 455 nm.
Full emission spectra (430−550 nm) were also recorded using a
PerkinElmer LS50B spectrophotometer.
Imaging of Iron Stored in BfrB and Analysis of Total Iron
Levels. Precultures were grown as described above, and cells were
diluted in M63 media supplemented with 4 μM Fe (6 μM total Fe) to
OD600 = 0.1 in 50 mL conical tubes. The resultant cell suspensions (5
mL) were mixed with a small volume of a 10 mM working solution of
analog 16 in DMSO to give a 125 μM solution and 2% DMSO, or
simply 2% DMSO (control). The conical tubes were covered with an
air permeable membrane, and the cultures were incubated at 35 °C
and 120 rpm for 6, 9, 12, 15, 18, 21, and 24 h. Prior to separating the
cells by centrifugation (4000 rpm, 15 min), a 100 μL aliquot was
withdrawn from each conical tube and serially diluted for plating and
enumerating viable cells. The separated pellet was washed with 5 mL
of PBS and frozen at −20 °C for subsequent analysis. The cell pellets
were used to image iron stored in BfrB according to a previously
described method19 with some minor modiﬁcations. Brieﬂy, cell
pellets were suspended in 300 μL of lysis buﬀer (50 mM Tris pH 8.0,
20% glycerol, 20 mg/mL lysozyme, 0.2 mg/mL DNase, 100 mM
NaCl, 10 mM MgCl2, and 1% Triton X) and freeze−thawed twice
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using liquid N2. The resultant suspensions were incubated at 25 °C
for 90 min in a rocker and then centrifuged at 12 500 rpm for 15 min
at 4 °C. Lysate solutions (100 μL) were each mixed with 10 μL of the
loading dye, and the samples (100 μL) were loaded onto a 3-mmthick native polyacrylamide gel (8% resolving gel and 4% stacking gel)
for separation. Electrophoretic separation was carried out at 60 V for 7
h at 4 °C, and the gels were stained with Ferene S47 for 10 min in a
solution containing 0.049 g of Ferene S, 250 μL of thioglycolic acid,
2.5 mL of acetic acid, and 100 mL of water. The scanned images were
processed and compared using ImageJ.48
To determine the total iron levels of cells treated with analog 16 or
DMSO only (control), 5 mL cultures were grown in M63 media
supplemented with 4 μM iron, as described above, and analyzed at 12,
15, 21, 24, and 28 h. Prior to separation of the cells by centrifugation
(4000 rpm, 15 min), a 100 μL aliquot was withdrawn from each
conical tube and serially diluted for plating, in order to enumerate
viable cells. Cell pellets were washed twice with 10 mL of PBS, and
the total levels of cellular iron were measured using a published
protocol.19,49 In brief, cell pellets were mixed with 500 μL of freshly
prepared digestion reagent (1:1 v/v 1.2 N HCl and 4.5% w/v KMnO4
in water), thoroughly mixed by vortexing, and incubated at 65 °C for
4 h. The digested solutions were cooled to 25 °C, mixed with 500 μL
of iron chelating agent (6.5 mM Ferene S, 13.1 mM neocuproine, 2 M
ascorbic acid, 5 M ammonium acetate), and then incubated at 25 °C
for 30 min. The iron concentration of the resultant solution was
measured from the absorbance of the Fe2+−Ferene S complex at 593
nm (ε = 34,500 M −1 cm −1 ) 50 using a Cary 60 UV−vis
spectrophotometer, normalized by cell count and reported as Fe
atoms per CFU (colony forming unit). The colorimetric determination of total intracellular iron oﬀers a sensitive, accurate, and low
cost analytical technique, which has been shown to produce results
similar to those obtained by atomic inductively coupled plasma-mass
spectrometry.51
Eﬀect of Analogs on the Potency of Fluoroquinolone
Antibiotics. Cultures were treated with (i) analog 16 only; (ii)
ciproﬂoxacin (0.25 μg/mL), levoﬂoxacin (0.5 μg/mL), or norﬂoxacin
(0.9 μg/mL) only; and (iii) both ﬂuorquinolone (concentration as
above) and analog 16. Precultures were grown as described above; the
cells were then diluted in M63 media supplemented with 4 μM Fe to
OD600 = 0.1 in 50 mL conical tubes. The resultant cell suspensions (5
mL) were mixed with a small volume of a 10 mM working solution of
analog 16 in DMSO to give the desired analog concentration (75,
100, or 125 μM) and 2% DMSO, or simply with DMSO (untreated
control). The conical tubes were covered with an air permeable
membrane, and the cultures were incubated for 18 h at 35 °C and 120
rpm. The resultant cultures were serially diluted in PBS and plated on
PIA for enumeration of viable cells. To treat cells with ciproﬂoxacin
only, the procedure was identical except that the cell suspensions (5
mL) were mixed with a small volume of ciproﬂoxacin working
solution (100 μg/mL) to give the desired antibiotic concentration and
2% DMSO. The combined treatment was carried out similarly,
ensuring that the ﬁnal concentration of DMSO was 2%.
Measurement of Dissociation Constants (Kd). Experimental
details are presented in the Supporting Information.

■

criteria (MW < 300 Da, clogP < 3, and total count of hydrogen
bond acceptors/donors <3 each). In addition, fragments
capable of π−π stacking were included with both electronrich and -deﬁcient aromatic rings. To screen the library in
search of fragments that bind BfrB at the Bfd-binding site we
developed a competition assay that utilizes saturation transfer
diﬀerence (STD) NMR spectroscopy. This technique is ideally
suited to screen fragments that bind to the large BfrB (∼440
kDa) because protein resonance assignments are not necessary
and very low protein concentrations are required. In addition,
the large rotational correlation time (τc) of BfrB enhances spin
diﬀusion and therefore saturation transfer within the protein
and to the ligand.52 Two solutions were prepared for each
fragment: a solution of the fragment alone, and a solution of
the fragment and BfrB. Three spectra were obtained for each
fragment, as illustrated in Figure S1 of the Supporting
Information for fragment 1, which binds BfrB at the Bfdbinding site. The 1H spectrum of the fragment alone was used
to determine fragment integrity and solubility, the 1H spectrum
of the fragment in the presence of BfrB was used to
corroborate that fragment integrity and solubility is not
aﬀected by BfrB, and the STD spectrum of the solution
containing the fragment and BfrB was used to assess fragment
binding. This strategy uncovered 18 compounds that bind
BfrB. The speciﬁcity criterion for fragment binders, however, is
that these bind BfrB speciﬁcally at the Bfd-binding site. To
eliminate nonspeciﬁc binders, a displacement strategy was
implemented that utilizes Bfd as a speciﬁc competitor. For this
purpose, an STD spectrum was acquired from a solution
containing fragment, BfrB and Bfd. Nearly complete
disappearance of the STD signal indicates that the fragment
binds BfrB at the Bfd-binding site. With the aid of this
competitive displacement strategy, it was determined that of
the 18 fragments that bind BfrB, the 6 molecules shown in
Chart 1 bind at the Bfd-binding site. These fragments were
advanced to the next stage, which was focused on uncovering
structural information on fragment binding. Results from these
experiments are presented below.
Structure-Based Optimization of Fragment Binders.
A structure-guided approach was used to synthetically
elaborate fragments discovered to bind BfrB at the Bfd-binding
Chart 1. Structures of Fragments Identiﬁed to Bind BfrB at
the Bfd-Binding Site Using the Screening Strategy
Described in the Text

RESULTS

Screening and Detection of Fragment Binding to the
Bfd Binding Site on BfrB. Structural information obtained
from the BfrB−Bfd complex was used to design a fragment
library to screen for molecules that bind BfrB at the Bfdbinding site. Bfd residues M1, Y2, and L5 and BfrB residues
L68 and E81 dominate the buried surface area at the protein−
protein interface (Figure 1C) and contribute signiﬁcantly to
the binding energy of the BfrB−Bfd complex.31 Consequently,
the fragment library was focused on fragments that may bind at
the sites occupied by Y2 and L5 from Bfd and included groups
with chemical properties similar to the aromatic and aliphatic
side chains of Tyr and Leu, also utilizing standard fragment
8174
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Figure 2. Protein−protein interaction interface of the BfrB−Bfd complex. Subunits A and B of a BfrB subunit dimer are colored gray and green,
respectively. (A) Residues Y2 and L5 of Bfd (cyan cylinders) are positioned within pockets at the BfrB subunit dimer interface. (B) Fo − Fc omit
map (orange mesh) contoured at 3σ showing 5-hydroxyaminoisoindoline-1,3-dione (fragment 1) bound within the cleft occupied by L5 in the
BfrB−Bfd complex. (C) Hydrogen bond interactions (dashed lines) between fragment 1 and BfrB. Water mediated contacts are indicated by the
solid lines.

Figure 3. (A) Schematic summary of the synthetic procedures employed to prepare analogs of fragments 1, 5, and 8 to form ethers 4 derived from
5-hydroxyisoindoline-1,3-dione (1); amines 6 or amides 7 derived from 5-aminoisoindoline-1,3-dione (5); or amines 9 or amides 10 derived from
4-aminoisoindoline-1,3-dione (8). Descriptions of the synthetic procedures, as well as the characterization of the analogs are presented in the
Supporting Information. (B) Structures of fragment 1 and analogs prepared from fragment 8, which have been shown to bind BfrB at the Bfd
binding site by X-ray crystallography.

site into analogs capable of binding with higher aﬃnity. The
aﬃnity and selectivity of the fragments and analogs for the Bfdbinding site on BfrB were investigated by X-ray crystallography, surface plasmon resonance (SPR), and ﬂuorescence
polarization methods. The structures of fragments and derived
analogs which have been demonstrated to bind BfrB at the
Bfd-binding site using X-ray crystallography are shown in
Figure 3B. During the course of these experiments, crystals

obtained from three diﬀerent BfrB constructs were tested in
ligand soaking experiments, in an eﬀort to identify the “best”
crystals for the study. Hence, crystals of BfrB (PDB 5D8O),
C98S/K96C BfrB (PDB 4TOF), and apo-BfrB were soaked in
crystallization solution containing the various analogs. The
structure of 5-hydroxyisoindoline-1,3-dione (fragment 1)
bound to BfrB was obtained by soaking crystals of C98S/
K96C BfrB in a solution of the fragment, as described in the
8175
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from 5 or 8, respectively, via reactions with a series of acid
chlorides. The collection of ether, amine, and amide analogs
prepared for this study, as well as the details of their synthetic
preparation and characterization, are presented in the
Supporting Information.
Although all of the compounds synthesized for each of the
analog types shown in Figure 3A were tested in crystal soaking
experiments, structures of analog-bound BfrB were obtained
only for analogs 11−16 (Figure 3B), which are derivatives of
4-aminoisoindoline-1,3-dione (8) with −(CH 2 )− and
−(CH2)3− linkers. The pose of each of these analogs in the
Bfd-binding site of BfrB is shown in Figures 4 and S3.

Experimental Section. In subsequent experiments, crystals of
apo-BfrB were used because this protein formed robust, highly
reproducible crystals. These experiments culminated in the
structure of analog 12 bound to BfrB. It is important to
underscore that the structure of apo-BfrB is nearly identical to
that of BfrB, at the subunit level (RMSD = 0.18 Å), as well as
the biological assembly level, including the Bfd-binding sites
(Figure S2A). Additional evidence indicating that the Bfdbinding sites on apo-BfrB are unaﬀected relative to the holoprotein was obtained in the dissociation constant for the
interaction between Bfd and apo-BfrB (Kd = 3.1 μM) (Figure
S2B and C), which is nearly identical to that previously
reported for the interaction between Bfd and holo-BfrB (Kd =
3.4 μM).31,53 Finally, the BfrB protein also produced
reproducible crystals that were isomorphs with those formed
by apo-BfrB. Consequently, the structures of analogs 11 and
13−16 bound to BfrB were obtained by soaking crystals of
BfrB in solutions of each of the analogs.
Figure 2A depicts a portion of the BfrB−Bfd complex
interface and illustrates how Y2 and L5 in Bfd (cyan cylinders)
contribute to anchor Bfd to the BfrB surface. A prior study
indicated that interactions between L68 and E81 in BfrB and
Y2 and L5 in Bfd contribute signiﬁcantly to the binding energy
of the BfrB−Bfd complex.31 It was therefore surmised that
fragments capable of binding to this region of the BfrB surface
would be good candidates for subsequent structure-guided
synthetic elaboration aimed at discovering inhibitors of the
BfrB−Bfd interaction. To obtain the structures of fragments
bound to BfrB, crystals of the protein were soaked in
crystallization solution containing each of the 6 fragments
found to bind BfrB at the Bfd-binding site with the aid of the
competitive displacement STD NMR strategy described above.
These eﬀorts culminated in a 1.5 Å resolution cocrystal
structure of 5-hydroxyisoindoline-1,3-dione (1) bound to BfrB
(Figure 2B and 2C and Table S1), which showed that 1 binds
BfrB at the Bfd-binding site, in the same pocket where L5 from
Bfd would bind. The fragment rests on a platform at the base
of a shallow depression on the BfrB surface formed by the side
79
chains of L77
B and IB (the subscript denotes subunit, and the
superscript denotes residue number), surrounded by a
semicircular wall comprised by the side chain and backbone
70
72
77
atoms of L68
A , NA , QA , and LB . One of the carbonyl-oxygen
atoms of 1 accepts a H-bond from the backbone NH of L71
A,
and its N−H group forms a H-bond to the backbone carbonyl
of P69
A . Additional stabilization for binding probably stems from
the network of H-bonded waters linking a carbonyl oxygen in 1
and G67
A in BfrB. This structural information suggested a
strategy to grow 1, or its analogs 4-aminoisoindoline-1,3-dione
(8) and 5-aminoisoindoline-1,3-dione (5), by branching from
the isoindoline ring carbons C4 or C5 to engage the cleft
formed by the side chains of L68 and E81 in BfrB, where Y2
from Bfd anchors.
A general synthetic approach (Figure 3A) was formulated to
generate a series of ether analogs represented by 4, amine
analogs represented by 6 or 9, and amide analogs represented
by 7 or 10. Preparation of the ether analogs of 4 started with
the esteriﬁcation of the acid groups in 4-hydroxyphthalic acid
2, followed by alkylation of the phenolic oxygen to produce 3
and subsequent base cleavage of the esters and cyclization to
produce the isoindoline-1,3-dione ethers 4. Synthesis of the
amine analogs represented by 6 and 9 was carried out by
reductive amination of 5 or 8, respectively, with a series of
aldehydes, whereas amide analogs 7 and 10 were obtained

Figure 4. Binding modes of analogs 11 and 16 at the Bfd-binding site
on BfrB. Subunits A and B of a BfrB subunit dimer are colored gray
and green, respectively. (A) Fo − Fc omit map (orange mesh)
contoured at 3σ from analog 11 bound at the Bfd-binding site on
BfrB. (B) Same as panel A but showing a diﬀerent perspective to
illustrate the two orientations modeled for the o-hydroxyphenyl ring
of analog 11. (C) Hydrogen bond interactions (dashed lines)
between analog 11 and BfrB. Water mediated contacts are indicated
by the solid lines. (D) Fo − Fc omit map (orange mesh) contoured at
3σ from analog 16 bound at the Bfd-binding site on BfrB. (E) Same as
panel D but rotated to illustrate the m-hydroxyphenyl ring of analog
16 positioned between the cleft formed by the side chains of L68
A and
E81
B in BfrB. (F) Hydrogen bond interactions (dashed lines) between
analog 16 and BfrB. Water mediated contacts are indicated by the
solid lines.

Inspection reveals that the isoindoline-1,3-dione moiety in all
the compounds invariably binds BfrB in a manner identical to
that described above for fragment 1 binding to BfrB (see
Figure 2). In addition, and as was expected, the benzyl portion
of the analogs extends to engage the cleft formed by the side
81
chains of L68
A and EB in BfrB via hydrophobic packing
interactions. The interactions experienced by analog 11 at the
Bfd-binding site on BfrB are illustrated in Figure 4A−C. Strong
electron density consistent with the compound can be
observed in 9 of the 12 subunits in the asymmetric unit; the
3 subunits in which compound 11 was not modeled displayed
electron density not associated with the protein at the Bfdbinding site, but this electron density was too weak to model
the ligand. The o-hydroxyphenyl ring of 11 is observed in two
orientations that diﬀer by a 180° rotation of the ring; one
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Table 1. Structure, Binding Aﬃnity, and IC50 of 4-Aminoisoindoline-1,3-dione Derivatives

waters connecting a carbonyl oxygen in the isoindoline-1,3dione ring, the hydroxyl group on aromatic ring, and the
carbonyl oxygen in L68
A . The structures of four additional
compounds similar to 16 bound to BfrB (Figure S3), which
show a nearly identical pose of the isoindoline-1,3-dione
moieties and very similar interactions of the linkers and phenyl
rings, demonstrate the speciﬁcity with which the series of 4amino derivatives listed in Table 1 engage the Bfd-binding site
on BfrB.
Prior to testing the eﬀect that the 4-substituted isoindoline1,3-dione derivatives might exert on P. aeruginosa cells, the
strength of their interaction with BfrB was evaluated in vitro
with a ﬂuorescence polarization assay developed based on the
intrinsic ﬂuorescence of the isoindoline-1,3-dione moiety.
Because initial ﬂuorescence spectroscopic measurements
revealed that the heme groups in BfrB interfere with the
signal of the ﬂuorescent ligand, we utilized apo-BfrB for these
measurements, capitalizing on our earlier ﬁndings that the Bfdbinding sites in apo-BfrB are nearly identical to those in BfrB,
and that the Kd for the interaction between apo-BfrB and Bfd is
very similar to that measured for the interaction between BfrB
and Bfd (see above and Figure S2). Hence, the Kd values were
measured by titrating apo-BfrB into a ﬁxed concentration of
the appropriate ﬂuorescent 4-aminoisondoline-1,3-dione ligand
while analyzing ﬂuorescence polarization and intensity near the
emission λmax (Figure S4). The Kd values (Table 1) show that

orientation places the hydroxyl group pointing toward the base
of the cleft, where it forms a hydrogen bond with G80
B , while
the second orientation places the hydroxyl group toward the
solvent and enables packing of the o-hydroxyphenyl ring and
the −(CH2)− moiety bridging the phenyl and isonindoline
79
rings against the side chains of M31
B and IB , respectively.
Additional stabilization for binding probably stems from the
network of H-bonded waters linking a carbonyl oxygen in 11
and G67
A , similar to the network of H-bonded water molecules
observed in the structure of 1 bound to BfrB (see Figure 2C).
The structure of a similar analog (12) bound to BfrB shows
identical interactions of the isoindoline-1,3-dione moiety with
BfrB and similar interactions of the phenyl ring with the cleft
81
formed by the side chains of L68
A and EB on the BfrB surface
(Figure S3A−C).
A similar close view of compound 16 bound at the Bfd
binding site on BfrB (Figure 4D−F) illustrates how the
isoindoline-1,3-dione ring presents the same pose and set of
interactions as those described above for fragment 1 and
analogs 11 and 12. Clear electron density consistent with the
compound can be observed in all 12 subunits in the
asymmetric unit, but the m-hydroxyphenyl ring was partially
disordered in several of the subunits. The m-hydroxyphenyl
ring and the −(CH2)3− linker pack against the L68
A and
hydrophobic portion of the E81
B side chains, with additional
stabilization probably stemming from a network of H-bonded
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and 5B illustrate the dose-dependent growth inhibition
observed upon challenging the cultures with analogs 11 and
16, respectively; the highest concentration of analog used was
determined by its solubility in PBS buﬀer, 250 μM for analog
11, and 125 μM for analog 16. Growth curves from similar
experiments conducted with the other analogs in Table 1 are
shown in Figure S5. In order to facilitate a quantitative
comparison of the eﬀect exerted by the analogs on P.
aeruginosa growth, IC50 values were calculated. To this end,
the growth inhibition caused by each of the analogs was
compared to that of the untreated culture (100% growth) and
to the growth in the presence of ciproﬂoxacin present at a
concentration equivalent to 3 times the reported MIC (0%
growth). Hence, the relative growth in the presence of a 4aminoisoindoline-1,3-dione analog, measured 13 h postinoculation, is deﬁned by eq 1 (see Experimental Section).
The IC50 values, obtained from ﬁtting the plots relating growth
% and analog concentration to eq 2 (Figures 5C, 5D and S5),
are listed in Table 1. Comparison of these values shows that
analog 16 is the most eﬃcacious at inhibiting cell growth,
despite a very similar binding aﬃnity for BfrB when compared
to similar analogs such as 13, 14, and 15. The reasons for the
higher eﬃcacy of analog 16 to inhibit cell growth are not yet
evident, but it is possible to speculate that these may be related
to their relative ability to penetrate the P. aeruginosa cell and/
or their reactivity/stability in cell culture.
To obtain initial insights on the selectivity of the analogs for
their intended target in P. aeruginosa, mutant cells with a
deletion of the bfrB gene (ΔbfrB) were challenged with analog
11 or 16. To this end, wild type and ΔbfrB cells were cultured
in M63 media supplemented with 4 μM Fe, in the presence of
diﬀerent concentrations of analog. The eﬀect of the analogs on
cell growth was evaluated 15 h postinoculation by plating and
enumerating viable cells and comparing the cell growth of each
strain to the corresponding untreated control (Figure 6A and

analogs 11−16 exhibit signiﬁcantly higher aﬃnity than
fragment 8, observations that are in agreement with the
structural insights, which revealed that growing the fragments
from the isoindoline ring carbon C4 make it possible to engage
the cleft formed by the side chains of L68 and E81 in BfrB.
The two derivatives with a −(CH2)− linker exhibit binding
aﬃnities approximately 2- to 5-fold lower than derivatives with
a −(CH2)3− linker, also in agreement with a relatively more
eﬃcient hydrophobic packing facilitated by the longer linker.
4-Aminoisoindoline-1,3-dione derivatives elicit a
growth retardation phenotype in P. aeruginosa cells.
The binding aﬃnity and structural information indicate that
most of the analogs in Table 1 bind BfrB at the Bfd binding site
with a strength comparable to that of the BfrB−Bfd association
(Kd = 3 μM), therefore suggesting that these compounds may
be capable of interfering with the BfrB−Bfd interaction in the
P. aeruginosa cytosol. As will be described below, this idea was
investigated, ﬁrst by demonstrating that the analogs elicit a
growth phenotype in P. aeruginosa, and then by showing that
one of the most potent analogs inhibits the mobilization of
iron from BfrB in the bacterial cytosol.
To investigate the eﬀect of the analogs on cell growth,
cultures of P. aeruginosa in M63 media were challenged with 4aminoisoindoline-1,3-dione derivatives, and their growth was
monitored in 96 well plates by following the OD600. Figure 5A

Figure 6. Deleting the bf rB gene (Δbf rB) changes the monophasic
dose-dependent growth response exhibited by the wild type P.
aeruginosa cells to analogs 16 and 11 into a biphasic response, which
is nearly independent of analog until ∼100 μM and rapidly toxic
thereafter. The plots illustrate the growth % of the Δbf rB (○) and
wild type (●) cells relative to untreated control as a function of
analog 16 (A) and analog 11 (B) concentration. The values at each
point are the average and standard deviation from three independent
experiments.

Figure 5. Analogs of 4-aminoisoindoline-1,3-dione elicit a growth
defect in P. aeruginosa. Panels (A) and (B) show the time-dependent
growth retardation of P. aeruginosa cultures treated with analogs 16
and 11, respectively. The black circles correspond to untreated cells
(DMSO control), and the open circles to cells treated with
ciproﬂoxacin (0.75 μg/mL). The concentrations of analog 16 in
(A) are 25 μM (red), 50 μM (green), 75 μM (yellow), 100 μM
(blue), and 125 μM (magenta); the concentrations of analog 11 in
(B) are 25 μM (red), 75 μM (yellow), 125 μM (magenta), 175 μM
(purple), and 250 μM (brown). The corresponding IC50 values (C
and D) were obtained by calculating the % growth using OD600 values
at 13 h and ﬁtting to eq 2, as indicated in the Experimental Section.
Each of the growth curves was constructed from the average and
standard deviation of 5 replicate wells. The IC50 values (see Table 1)
are the average and standard deviation from three independent
experiments.

B). As expected, the analogs elicit a monophasic dosedependent growth defect on the wild type cells. In comparison,
the analogs induce a biphasic growth response on the Δbf rB
mutant cells, which consists of a shallow ﬁrst phase (0−∼100
μM) that is nearly independent of analog concentration,
followed by a steep second phase where the analogs become
rapidly toxic. Since BfrB is not essential, it is likely that the cell
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Figure 7. P. aeruginosa cells treated with analog 16 overproduce pyoverdin. (A) P. aeruginosa cultures treated with analog 16 (125 μM) for 13 h
exhibit approximately 30% of the viable cells in the untreated DMSO control. (B) Fluorescence spectra obtained from cell free supernatants (13 h
postinoculation) after a 500-fold dilution in PBS buﬀer, pH 7.4. The black trace is the spectrum from pyoverdin present in cell-free supernatant
from untreated cells (DMSO control), and the red trace is the spectrum from pyoverdin in cell-free supernatant from samples treated with analog
16 (125 μM). The green trace was obtained after a 125 μM solution of analog 16 in M63 media was diluted 500-fold in PBS, to show that the
relatively weak intrinsic ﬂuorescence of the analog does not interfere with the strong ﬂuorescence response from pyoverdin. (C) Fluorescence
intensity normalized to the number of viable cells (CFU/mL) shows that cells treated with analog 16 secrete ∼4.5-fold more pyoverdin than cells
in the DMSO control. Error bars represent standard deviations from three independent experiments.

Figure 8. Analog 16 inhibits iron mobilization from BfrB in P. aeruginosa. Cells cultured in M63 media supplemented with 4 μM Fe were treated
with analog 16 (125 μM) or with an equivalent volume of DMSO (control). (A) Enumerating viable cells shows that cultures treated with analog
16 (open circles) have approximately 2.5-fold fewer cells than untreated control (black circles) at all time points. (B) The iron stored in BfrB was
visualized with the aid of native PAGE gels stained with Ferene S, which stains the iron stored in the interior cavity of BfrB blue. Recombinant BfrB
(Rec. BfrB) was used to show the electrophoretic mobility of BfrB in the native PAGE gels. Lanes loaded with lysates of untreated control (DMSO)
show iron stored in BfrB, with maximum accumulation in late exponential growth (ca. 15 h) and subsequent mobilization in the stationary phase.
Lanes loaded with lysates of untreated control diluted 2-fold (0.5× DMSO) to account for the 2-fold larger number of viable cells in the untreated
cultures show a similar trend. Lanes loaded with lysates of cells treated with 16 show signiﬁcant inhibition of iron mobilization from BfrB. (C) Plot
of peak areas obtained from densitometry analysis of the native PAGE gels in panel B. The open circles track the peak area in lanes loaded with
lysates of cells treated with 16, while the black circles track the peak area from the untreated control (0.5× DMSO). (D) Analysis of total iron levels
normalized to viable cell count (CFU/mL) shows approximately 2-fold higher iron levels in cells treated with 16 (white bars), in agreement with
nearly irreversible iron accumulation in BfrB. Error bars represent the standard deviation of three independent experiments. Panels B and C show
results from a representative experiment.

the dose-dependent growth defect elicited by 11 or 16 on wild
type P. aeruginosa cells is largely a consequence of the
interaction between the small molecule inhibitors and BfrB in
the bacterial cell. This issue was investigated in additional
detail by probing the phenotypic and biochemical response of
wild type cells treated with the small molecule inhibitors. The
results of these studies are presented below.
4-Aminoisoindoline-1,3-dione derivatives engage
their target (BfrB) in P. aeruginosa cells. Studies

can compensate for the absence of the iron storage protein.
Nevertheless, the nearly independent growth defect observed
in the ﬁrst phase, which is in good agreement with the absence
of BfrB, supports the idea that analogs 11 and 16 exhibit
signiﬁcant selectivity for BfrB in the P. aeruginosa cell. The
sudden onset of toxicity observed in the second phase, which is
not observed with the wild type cells, is probably related to oﬀtarget eﬀects that expose a ﬁtness vulnerability caused by the
absence of BfrB. Consequently, it is possible to conclude that
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Figure 9. Analog 16 potentiates the activity of ﬂuoroquinolones. (A−C) P. aeruginosa PAO1 cultures in M63 media supplemented with 4 μM iron
were treated with analog 16 only, ﬂuoroquinolone at the reported MIC only, and a combination of analog 16 and ﬂuoroquinolone at the MIC. The
ﬂuoroquinolones studied are (A) ciproﬂoxacin (0.25 μg/mL), (B) levoﬂoxacin (0.5 μg/mL), and (C) norﬂoxacin (0.9 μg/mL). (D) P. aeruginosa
clinical isolate MR3B cultures in M63 media supplemented with 4 μM iron were treated with analog 16 only, or ciproﬂoxacin only (0.2 μg/mL), or
a combination of 16 and ciproﬂoxacin. (E) P. aeruginosa clinical isolate MR60 cultures in the same media as above were treated with analog 16, or
ciproﬂoxacin (1.0 μg/mL), or a combination of 16 and ciproﬂoxacin. Error bars represent the standard deviation from three independent
experiments.

dilution in PBS is shown in the green trace of Figure 7B.
Similar observations are made when cell cultures are treated
with analog 11 (Figure S6), albeit with a less pronounced
phenotype, which is in agreement with the lower aﬃnity of the
analog for BfrB and correspondingly higher IC50. These
ﬁndings, which indicate that the analogs elicit the anticipated
pyoverdin hyper-production phenotype in P. aeruginosa,
suggest that they bind BfrB in the P. aeruginosa cytosol,
block the BfrB−Bfd interaction, and inhibit iron mobilization
from BfrB.
To obtain additional evidence that 16 blocks the BfrB−Bfd
interaction and inhibits iron mobilization from BfrB in the P.
aeruginosa cytosol, we resorted to visualizing BfrB-iron in
native PAGE gels stained with Ferene S. A similar approach
has been used to demonstrate that the Δbfd mutant irreversibly
accumulates iron in BfrB.19 To this end, cells cultured in M63
media supplemented with 4 μM iron were treated with 16
(125 μM) or with an equivalent volume of DMSO (control).
At diﬀerent time points cells were harvested by centrifugation
after a small aliquot had been sampled to enumerate cell
density (CFU/mL). The growth curves (Figure 8A) show that
at every time point the number of viable cells in the untreated
cultures is approximately 2.5-fold larger than in cultures treated
with 16. To visualize iron stored in BfrB, the cells harvested at
diﬀerent time points were lysed and the clariﬁed supernatants
were loaded onto native PAGE gels for separation and
subsequent staining with Ferene S (Figure 8B); recombinant
BfrB mineralized with an iron core of approximately 400 iron
ions was used as a standard for the electrophoretic mobility of
BfrB. Lanes loaded with lysate from untreated cells (DMSO)
show that iron accumulating in BfrB reaches a maximum at ca.
15 h and then is mobilized. A similar trend is observed if the
lysate solutions of untreated cells are diluted 2-fold prior to
loading the gels (0.5× DMSO in Figure 8B), in order to
account for the nearly 2-fold larger CFU/mL observed at each

conducted to determine whether the analogs are capable of
engaging BfrB and inhibiting iron mobilization from the
bacterioferritin in the P. aeruginosa cytosol were conducted
mainly with the most eﬃcacious analog (16), and when
practical, also with analog 11, which is the most active of the
two compounds harboring a −(CH2)− linker. As indicated
above, genetic manipulations were used in prior work to delete
the bfd gene (Δbfd) and evaluate the consequences of
inhibiting the BfrB−Bfd interaction in P. aeruginosa.19
Preventing the BfrB−Bfd interaction in the Δbfd mutant
cells dysregulates iron homeostasis by causing the irreversible
accumulation of iron in BfrB and the concomitant depletion of
free iron levels in the cytosol. The resultant phenotype is
overproduction of the siderophore pyoverdin, which is ∼4-fold
larger than that secreted by wild type cells.19 If the 4aminoisoindoline-1,3-dione analogs are capable of binding
BfrB, blocking the BfrB−Bfd interaction, and consequently
inhibiting iron mobilization from BfrB in the P. aeruginosa
cytosol, then they would be expected to elicit a similar
pyoverdin hyper-production phenotype. To investigate
whether 4-aminoisoindoline-1,3-dione derivatives indeed elicit
such a phenotype, P. aeruginosa cells cultured in M63 media
were treated with analog 16 at a concentration of 125 μM. As
expected, cell cultures treated with the analog exhibited ca.
30% of viable cells relative to cells in the untreated control
(Figure 7A). To analyze the levels of secreted pyoverdin, cells
were pelleted and the supernatant was diluted 500-fold prior to
measuring the ﬂuorescence intensity at 455 nm (Figure 7B).
Normalizing the intensity of pyoverdin ﬂuorescence to cell
density (CFU/mL) shows that cells treated with 16 secrete
∼4-fold more pyoverdin than the untreated control (Figure
7C). To demonstrate that the intrinsic ﬂuorescence of 16,
which is signiﬁcantly weaker than that of pyoverdin, does not
interfere with the measurement, the ﬂuorescence spectrum
from a solution of analog 16 (125 μM) after a 500-fold
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with ciproﬂoxacin (0.2 μg/mL) experienced ca. 10% survival.
In comparison, cultures treated with a combination of analog
16 and ciproﬂoxacin experienced 0.5% survival, or approximately 20-fold lower survival relative to treatment with
ciproﬂoxacin alone. Strain MR60 is signiﬁcantly more resistant
to ciproﬂoxacin. When treated with ciproﬂoxacin at a
concentration of 1 μg/mL, which is 4−5-fold higher than the
dose used in experiments with strain PAO1 or MR3B, the
MR60 strain experienced ca. 90% survival (Figure 9E). In
comparison, MR60 cultures treated with analog 16 (125 μM)
experienced ca. 40% survival and cultures treated with a
combination of analog 16 and ciproﬂoxacin experienced ca.
10% survival, or approximately 4-fold lower survival relative to
treatment with ciproﬂoxacin alone. These ﬁndings indicate that
analogs of 4-aminoisoindoline-1,3-dione, such as analog 16,
have the potential for inhibiting the BfrB−Bfd interaction and
enhance the activity of ﬂuoroquinolones in a variety of P.
aeruginosa strains.

time point relative to the treated culture. In contrast, the lanes
loaded with lysates obtained from cultures treated with 16
show only iron accumulation in BfrB. The distinct trends of
iron accumulation in BfrB observed with the treated vs
untreated (0.5× DMSO) cultures can be readily visualized in
the plot of Figure 8C, which was constructed with the aid of
densitometry analysis of the gel bands. It is evident that the
untreated cells store iron in BfrB during the logarithmic growth
phase and then mobilize the stored reserves during the
stationary phase. In contrast, when cells are treated with 16,
the ﬂow of iron into BfrB appears to be mostly unidirectional,
with much slower (inhibited) mobilization of iron from BfrB.
Consistent with the nearly irreversible accumulation of iron in
BfrB when cultures are treated with 16, measurements of total
cellular iron levels normalized to viable cell counts show that P.
aeruginosa cells harbor approximately twice as much iron in the
treated cultures relative to the untreated control (Figure 8D).
Taken together, these observations strongly support the idea
that blockade of the BfrB−Bfd interaction by 16 inhibits iron
mobilization from BfrB and leads to nearly an irreversible
accumulation of unusable iron in the bacterial cell.
4-Aminoisoindoline-1,3-dione derivatives enhance
the killing activity of ﬂuoroquinolones. Previous studies
demonstrated that intact iron homeostasis is essential for
bacterial cell survival under antibiotic stress, which suggests
that bacterial iron homeostasis may be a potential target for
boosting the action of antibiotics.54,55 Consequently, we asked
if the 4-aminoisoindoline-1,3-dione probes developed to
disrupt bacterial iron homeostasis by blocking the BfrB−Bfd
interaction would also potentiate the killing activity of
antibiotics. The idea was initially tested by treating P.
aeruginosa PAO1 cultures with (i) analog 16, (ii) ciproﬂoxacin
at the reported MIC45 (0.25 μg/mL), and (iii) a combination
of ciproﬂoxacin and analog 16. The eﬀect was evaluated 18 h
post treatment by plating, enumerating viable cells (CFU/mL),
and comparing the results to untreated cells (Figure 9A).
Cultures treated with only analog 16 (125 μM) experienced
the anticipated ∼30% survival, and cultures treated with only
ciproﬂoxacin experienced approximately 10% survival relative
to untreated control. In comparison, cultures treated with a
combination of ciproﬂoxacin and analog 16 experienced
signiﬁcantly lower survival, in an analog-concentration dependent manner, such that when analog 16 was present at 125 μM
the % survival was ∼50-fold lower relative to treatment with
ciproﬂoxacin alone. Similar experiments carried out with the
ﬂuoroquinolones levoﬂoxacin and norﬂoxacin revealed a
similar enhancement of bactericidal activity, with approximately 50-fold lower cell survival of cultures treated with a
combination of 16 (125 μM) and ﬂuoroquinolone, relative to
treatment with only the ﬂuoroquinolone. Related experiments
conducted with tobramycin and gentamycin (protein synthesis
inhibitors) and with ceftazidime and imipenem (cell wall
biosynthesis inhibitors) showed no enhancement of the
antibacterial activity of these antibiotics when used in
combination with the small molecule inhibitors of the BfrB−
Bfd interaction (data not shown).
To extend these observations to include additional strains of
P. aeruginosa, we conducted similar investigations with two
cystic ﬁbrosis clinical isolates (MR3B and MR60) obtained
from Seattle Children’s Research Foundation. Observations
made with strain MR3B (Figure 9D) are similar to those made
with strain PAO1 in that cultures of M3B treated with analog
16 (125 μM) experienced ca. 50% survival and cultures treated

■

DISCUSSION
Iron metabolism is emerging as an important unconventional
target for the development of antibacterial strategies. The
essentiality of iron for most pathogens, together with innate
immune defenses which function to maintain very low
concentrations of free iron in vivo (∼10−20 M), present a
formidable challenge to host colonization by pathogens and
suggest that dysregulation of iron homeostasis constitutes a
signiﬁcant bacterial vulnerability. In agreement, gallium has
been shown to disrupt bacterial iron metabolism,56,57 and a
recent report showed that systemic gallium treatment improves
lung function in patients with chronic P. aeruginosa infection.11
Ga3+, which has an ionic radius similar to that of Fe3+, is
thought to perturb iron homeostasis by replacing Fe3+ in vital
iron-utilizing proteins. Since Ga3+ cannot be reduced under
physiological conditions, iron-utilizing proteins become
inhibited, adversely aﬀecting important metabolic paths.
These observations, which underscore the signiﬁcance of
targeting iron metabolism as a viable approach to treat
infections, also highlight the importance of developing rational
means to dysregulate bacterial iron homeostasis to validate
new targets and implement new strategies to develop novel
antimicrobial therapies.
Previous investigations with P. aeruginosa showed that
bacterial iron homeostasis can be perturbed by speciﬁcally
interfering with the process of iron storage/mobilization from
bacterioferritin.19 Encouraged by these results we pursued a
systematic, iterative strategy based on fragment screening,
structural characterization of fragment binding, and synthetic
elaboration of fragment hits to discover inhibitors of the BfrB−
Bfd protein−protein interaction (Table 1). These small
molecule analogs of 4-aminoisoindoline-1,3-dione selectively
bind BfrB at the Bfd binding site and engage pockets on the
BfrB surface where Y2 and L5 from Bfd anchor. X-ray
crystallographic studies showed that all analogs in Table 1 bind
at the Bfd-binding site on BfrB with nearly identical poses and
interactions. These observations, which underscore the
selectivity of the analogs for the Bfd-binding site on the BfrB
surface, validate the structure-guided approach that led to their
identiﬁcation as inhibitors of the protein−protein interaction.
The binding selectivity of the analogs for the Bfd binding site
on BfrB endows analogs such as 16 with their ability to bind
BfrB in the P. aeruginosa cytosol, perturb its interaction with
Bfd, and inhibit the mobilization of BfrB-iron. Consequently,
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the observations reported herein constitute proof of concept
for the usefulness of chemical probes designed to perturb iron
homeostasis by rationally interfering with a speciﬁc protein−
protein interaction in the bacterial cell. Blockade of the BfrB−
Bfd interaction with these chemical probes inhibits iron
mobilization from BfrB and establishes a nearly unidirectional
ﬂow of iron into BfrB, which causes a signiﬁcant fraction of the
cellular iron to be “trapped” in BfrB and, therefore, accumulate
as an unusable resource for the cell. The nearly irreversible
accumulation of iron in BfrB is probably accompanied by a
depletion of free iron in the cytosol, similar to that observed
with the Δbfd mutant,19 which, as expected, is manifested in a
pyoverdin hyperproduction phenotype. In this context, the
growth defect elicited by the inhibitors is probably related to
an intracellular iron limitation induced by blockade of the
BfrB−Bfd interaction, which in turn is likely to exert an
inhibitory eﬀect on the biosynthesis and repair of irondependent enzymes that function in central physiological
processes. Hence, the chemical probes reported herein provide
a valuable starting point for future studies of structure−activity
relationships that could lead to the identiﬁcation of higheraﬃnity analogs as potential therapeutic lead compounds.
An important feature of utilizing chemical probes for
dissecting biological systems is that these can be used alone,
or in combination with other synergistic or antagonistic
probes. Previous studies have shown that some antibiotics
disrupt bacterial iron homeostasis and that the iron homeostasis machinery is important for bacterial cell survival in the
presence of antibiotics.54,58,59 Given that our results show that
the inhibitors of the BfrB−Bfd interaction dysregulate iron
homeostasis, we asked if the inhibitors would also boost the
activity of antibiotics. This idea was tested initially with
ciproﬂoxacin, and then with two other ﬂuoroquinolones,
norﬂoxacin and levoﬂoxacin. The results show that the small
molecule inhibitors of the BfrB−Bfd interaction boost the
bactericidal activity of the ﬂuoroquinolones approximately 50fold. Additional work is clearly required to understand the
reasons behind these observations. It is tempting, however, to
speculate that the enhancement of the killing activity brought
by the inhibitors of the BfrB−Bfd interaction may be related to
the intracellular iron depletion caused by inhibiting the
mobilization of iron from BfrB, which limits the pool of iron
required to support the biogenesis or the repair of irondependent enzymes. In this context, it has been proposed that
bactericidal antibiotics have well-established mechanisms of
action, but that, in addition to these distinct mechanisms,
subsequent metabolic changes such as elevated concentrations
of TCA metabolites, active breakdown of the metabolic pool,
and an elevated redox state also contribute to deﬁning
bactericidal activity.60 It is therefore possible that the
intracellular limitation of iron caused by inhibition of the
BfrB−Bfd interaction impairs the biogenesis or the repair of
important enzymes such as aconitase and succinate dehydrogenase of the TCA cycle, thus decreasing cell ﬁtness and
increasing the bacterial cell susceptibility to ﬂuoroquinolone
antibiotics. Consequently, it is possible to conceive a potential
therapeutic strategy where inhibitors of the BfrB−Bfd
interaction are used in combination with existing ﬂuoroquinolone antibiotics.
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I. W.; Echols, N.; Headd, J. J.; Hung, L.-W.; Kapral, G. J.; GrosseKunstleve, R. W.; McCoy, A. J.; Moriarty, N. W.; Oeffner, R.; Read, R.
J.; Richardson, D. C.; Richardson, J. S.; Terwilliger, T. C.; Zwart, P.
H. PHENIX: A Comprehensive Python-Based System for Macromolecular Structure Solution. Acta Crystallogr., Sect. D: Biol.
Crystallogr. 2010, 66, 213−221.
(41) Emsley, P.; Lohkamp, B.; Scott, W. G.; Cowtan, K. Features
and Development of Coot. Acta Crystallogr., Sect. D: Biol. Crystallogr.
2010, 66, 486−501.
(42) Liebschner, D.; Afonine, P. V.; Moriarty, N. W.; Poon, B. K.;
Sobolev, O. V.; Terwilliger, T. C.; Adams, P. D. Polder maps:
improving OMIT maps by excluding bulk solvent. Acta Cryst. D 2017,
73 (2), 148−157.
(43) Chen, V. B.; Arendall, W. B. r.; Headd, J. J.; Keedy, D. A.;
Immormino, R. M.; Kapral, G. J.; Murray, L. W.; Richardson, J. S.;
Richardson, D. C. MolProbity: All-Atom Structure Validation for
Macromolecular Crystallography. Acta Crystallogr., Sect. D: Biol.
Crystallogr. 2010, 66, 12−21.
(44) McNicholas, S.; Potterton, E.; Wilson, K. S.; Noble, M. E.
Presenting your Structures: The CCPmg Molecular-Graphics
Software. Acta Crystallogr., Sect. D: Biol. Crystallogr. 2011, 67, 386−
394.
(45) Andrews, J. M. Determination of Minimum Inhibitory
Concentrations. J. Antimicrob. Chemother. 2001, 48 (Suppl.1), 5−16.
(46) Sebaugh, J. L. Guidelines for accurate EC50/IC50 estimation.
Pharm. Stat 2011, 10 (2), 128−34.
(47) Chung, M. C. A specific iron stain for iron-binding proteins in
polyacrylamide gels: application to transferrin and lactoferrin. Anal.
Biochem. 1985, 148 (2), 498−502.
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